Search for Clinical Trial Results

Sponsored By

Hereditary Leiomyomatosis and Renal Cell Cancer - 3 Studies Found

Status Study
Recruiting Study Name: A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Condition:
  • HLRCC
  • Metastatic Papillary RCC

Date: 2010-05-25
Interventions:
  • Drug: Bevacizumab Commercially
Completed Study Name: Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Condition:
  • Cutaneous Leiomyomas
  • Hereditary Leiomyomatosis and Renal Cell Cancer Date: 2009-09-03
    Interventions:
    • Biological: Botulinum toxin type A

Recruiting Study Name: Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Condition:
  • Renal Cell Carcinoma
  • Hereditary Leiomyomatosis and Renal Cell Cancer Date: 2015-07-08
    Interventions:
    • Drug: Vandetanib Vandetanib is